Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)

This article was originally published in PharmAsia News

Executive Summary

Merck played cat and mouse on the first quarter earnings call, but its subsequent deal with Bayer put the remarks in context. Bristol Myers Squibb has to wait on China for approval there of its diabetes deal with AstraZeneca and Novo Nordisk gets hit by emerging market currencies.


Related Content

Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts